Merck & Co., Inc. (BMV:MRK)
Mexico · Delayed Price · Currency is MXN | Market Cap | 6.60T +66.8% |
| Revenue (ttm) | 1.16T +4.6% |
| Net Income | 55.44B -80.7% |
| EPS | 22.24 -80.4% |
| Shares Out | n/a |
| PE Ratio | 119.08 |
| Forward PE | 17.23 |
| Dividend | 59.77 (2.22%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 25 |
| Open | 2,690.00 |
| Previous Close | 2,521.50 |
| Day's Range | 2,690.00 - 2,690.00 |
| 52-Week Range | 1,531.00 - 2,690.00 |
| Beta | 0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase ...
Merck's Keytruda Is Dealt a Legal Setback. It's Good News for This Biotech Stock.
A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets.
Halozyme wins court order to block Merck's injected Keytruda in select European markets
Biopharma company Halozyme said on Wednesday that a Dutch patent court ruled in its favor against Merck , ordering the drugmaker to halt the manufacture and sale of injectable Keytruda in eight Euro...
Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29.
Merck says experimental skin disease drug meets main goal in mid-stage study
Merck said on Wednesday its experimental drug met the main goal of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps,...
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from MK-7240-012, a Phase 2b mul...
US drugmakers turn to China for licensing deals
Merck on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug, making it the latest US drugmaker to license China-develop...
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion
Merck said on Monday it would pay up to $2.13 billion under a global licensing deal with China's SciBrunch Therapeutics for rights to develop, manufacture and sell an experimental cancer treatment.
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (“SciBrunch”), today announced that they have entered into ...
Merck, Daiichi Sankyo withdraw US application for lung cancer drug
Merck and Daiichi Sankyo have voluntarily withdrawn their US application seeking accelerated approval for their experimental lung cancer therapy, the drugmakers said on Friday.
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
TOKYO--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as MSD outside of the United Stat...
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves WELIREG Plus LENVIMA for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Compone...
Merck's eye disease drug meets main goal in trial
Merck said on Thursday its drug met the main goal in a mid- to late-stage trial testing it in adult patients with a type of disease that affects blood vessels at the back of the eye.
Merck's Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabet...
U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. p...
Pharmaceutical Companies Push Trump Administration to Protect China Deals
A surge in U.S.-China transactions is drawing scrutiny in Washington, where some lawmakers are pushing to slow the pace of investment.
Merck's KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA ...
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (...
Moderna's AI-Built Cancer Vaccine Clears Phase 3 With Merck
Moderna built an artificial intelligence that reads a patient's tumor and decides what that patient's medicine should be. That approach just cleared its biggest test.
Merck & Co. Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Transformation is progressing with strong product launches, positive clinical data, and business development driving growth. Pipeline assets like INT and sac-TMT offer significant upside, while LIPFENDRA is positioned for broad access. AI and global innovation are enhancing R&D efficiency.
REVOLUTIONIZING HEALTHCARE: Tempus partners with Merck on AI-driven precision medicine
Tempus CEO Eric Lefkofsky discusses the company's artificial intelligence-driven precision medicine partnership with Merck on ‘The Claman Countdown.'
Merck & Co. Transcript: Wells Fargo 21st Annual Healthcare Conference
Significant progress was reported in portfolio transformation, with projected human health revenues rising to over $70B by the mid-2030s. Oncology and non-oncology pipelines are advancing, with new launches, robust clinical data, and strategic investments supporting long-term growth.
The Big 3: ROST, MRK, AAPL
Don Kaufman (@Theotrade) calls the U.S. Treasury's $6 billion bond buyback plan "nominal" to investors seeking relief as the inflation picture gets wider by the day. However, he sees bearish opportuni...
AI & Robotics in 2026: 16 Recent Developments for Investors
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference,...
Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference.